291
Views
0
CrossRef citations to date
0
Altmetric
Original Research

A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database

ORCID Icon, , &
Pages 381-387 | Received 15 Mar 2023, Accepted 20 May 2023, Published online: 12 Jul 2023

References

  • Farinelli I, Martelletti P. Aspirin and tension-type headache. J Headache Pain. 2007 Feb;8(1):49–55. doi: 10.1007/s10194-006-0357-4
  • Rolnik DL, Nicolaides KH, Poon LC. Prevention of preeclampsia with aspirin. Am J Obstet Gynecol. 2022 Feb;226(2s):S1108–s1119. doi: 10.1016/j.ajog.2020.08.045
  • Belhomme N, Doudnikoff C, Polard E, et al. Aspirin: Indications and use during pregnancy. Rev Med Interne. 2017 Dec;38(12):825–832.
  • Lecchi M, D’Alonzo L, Negro A, et al. Pharmacokinetics and safety of a new aspirin formulation for the acute treatment of primary headaches. Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1381–1395.
  • Herszényi L, Farinati F, Miheller P, et al. Chemoprevention of colorectal cancer: feasibility in everyday practice? Eur J Cancer Prev. 2008;17(6):502–514. doi: 10.1097/CEJ.0b013e3282f0c080
  • Lubbe WF. Prevention of preeclampsia by low dose aspirin. NZ Med J. 1990;103(890):237–238.
  • Lyons RA, Ford DV, Moore L, et al. Use of data linkage to measure the population health effect of non-health-care interventions. Lancet. 2014;383(9927):1517–1519. doi: 10.1016/S0140-6736(13)61750-X
  • de Oliveira ABM, Luchiari B, Bonilha I, et al. Aspirin in primary prevention and the risk of heart failure: a systematic review and meta-analysis of controlled trials. ESC Heart Fail. 2023 Apr;10(2):1488–1491.
  • Navaratnam K, Alfirevic A, Alfirevic Z. Low dose aspirin and pregnancy: how important is aspirin resistance? BJOG: Int J Obstet Gy. 2016 Aug;123(9):1481–1487. doi: 10.1111/1471-0528.13914
  • https://en.wikipedia.org/wiki/Adverse_event.
  • Shu Y, He X, Liu Y, et al. A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system. Clin Epidemiol. 2022;14:789–802. doi: 10.2147/CLEP.S365513
  • Li Y, Jimeno Yepes A, Xiao C. Combining social media and FDA adverse event reporting system to detect adverse drug reactions. Drug Saf. 2020 Sep;43(9):893–903. doi: 10.1007/s40264-020-00943-2
  • Liu S, Wei M, Moore R, et al. RxNorm: prescription for electronic drug information exchange. IT Prof. 2005;7(5):17–23. doi: 10.1109/MITP.2005.122
  • Brown EG. Using MedDRA: implications for risk management. Drug Saf. 2004;27(8):591–602. doi: 10.2165/00002018-200427080-00010
  • Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004 Aug;13(8):519–523. doi: 10.1002/pds.1001
  • Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001 Oct;10(6):483–486. doi: 10.1002/pds.677
  • Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998 Jun;54(4):315–321.
  • O'Neill RT, Szarfman A . [Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system]: discussion. Am Stat. 1999;53(3):190–196.
  • Joudi N, Rode M. Aspirin in pregnancy: a review of indications, timing, dosing and efficacy. Curr Opin Obstet Gynecol. 2023 Apr 1;35(2):94–100.
  • D’Antonio F, Khalil A, Rizzo G, et al. Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2023 Feb;5(2):100803.
  • Turner JM, Robertson NT, Hartel G, et al. Impact of low-dose aspirin on adverse perinatal outcome: meta-analysis and meta-regression. Ultrasound Obstet Gynecol. 2020 Feb;55(2):157–169.
  • Wang X, Wang H, Zheng Q, et al. Outcomes Associated with 50 mg/d and 100 mg/d aspirin for the prevention and management of cardiovascular disease in Chinese elderly: single-center interim analysis of a multicenter, prospective, observational study. Int J Gen Med. 2022;15:7089–7100. doi: 10.2147/IJGM.S384375
  • DiNicolantonio JJ, Norgard NB, Meier P, et al. Optimal aspirin dose in acute coronary syndromes: an emerging consensus. Future Cardiol. 2014 Mar;10(2):291–300.
  • Sample D, Wargovich M, Fischer SM, et al. A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. Cancer Epidemiol Biomarkers Prev. 2002 Mar;11(3):275–279.
  • Zhang Q, Ding Q, Yan S, et al. Fatal adverse events of dabigatran combined with aspirin in elderly patients: an analysis using data from VigiBase. Front Pharmacol. 2021;12:769251. doi: 10.3389/fphar.2021.769251
  • Lowenstern A, Newby LK. In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events. Ann Intern Med. 2017 Sep 19;167(6):Jc28.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.